Zecca C, et al. - An analysis was performed of the effectiveness and retention of fingolimod in a real-life Swiss setting, wherein individuals could receive fingolimod both as first or second line treatment for relapsing remitting multiple sclerosis (RRMS). Maximum subjects under fingolimod treatment illustrated freedom from relapses and disability progression in this Swiss cohort of naïve and pre-treated RRMS individuals. Data also revealed high treatment retention rate over 2 and 3 years, regardless of prior treatment.